Drug
Ianalumab
Ianalumab: highest development phase Phase 3, developed by Novartis. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ianalumab NCT06133972 | Phase 3 | Systemic Lupus Erythematosus |
| Ianalumab NCT05653219 | Phase 3 | Primary Immune Thrombocytopenia |
| Ianalumab NCT05653349 | Phase 3 | Primary Immune Thrombocytopenia (ITP) |
| Ianalumab NCT06711887 | Phase 3 | Lupus Nephritis |
| Ianalumab NCT06470048 | Phase 2 | Diffuse Cutaneous Systemic Sclerosis |
| ianalumab NCT07421167 | Phase 2 | Primary Immune Thrombocytopenia (ITP) |
Latest
Follow Ianalumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.